Your browser doesn't support javascript.
COVID-19 associated mucormycosis - An emerging threat.
Chao, Chien-Ming; Lai, Chih-Cheng; Yu, Wen-Liang.
  • Chao CM; Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying, Tainan, 73657, Taiwan; Department of Dental Laboratory Technology, Min-Hwei College of Health Care Management, Tainan, 73657, Taiwan. Electronic address: ccm870958@yahoo.com.tw.
  • Lai CC; Department of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan Branch, Tainan, 71051, Taiwan. Electronic address: dtmed141@gmail.com.
  • Yu WL; Department of Intensive Care Medicine, Chi Mei Medical Center, Tainan, 71004, Taiwan; Department of Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, 11031, Taiwan. Electronic address: Yuleon_md@yahoo.com.tw.
J Microbiol Immunol Infect ; 55(2): 183-190, 2022 Apr.
Article in English | MEDLINE | ID: covidwho-1882247
ABSTRACT
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly become a global threaten since its emergence in the end of 2019. Moreover, SARS-CoV-2 infection could also present with co-infection or secondary infection by other virus, bacteria, or fungi. Among them, mucormycosis is a rare but aggressive fungal disease and it mainly affects patients particularly with poorly controlled diabetes mellitus with diabetic ketoacidosis (DKA). We here did a comprehensive review of literature reporting COVID-19 associated with mucormycosis (CAM) cases, which have been reported worldwide. The prevalence is higher in India, Iran, and Egypt than other countries, particularly highest in the states of Gujarat and Maharashtra in India. Poor diabetic control and the administration of systemic corticosteroids are the common precipitating factors causing mucormycosis in the severe and critical COVID-19 patients. In addition, COVID-19 itself may affect the immune system resulting in vulnerability of the patients to mucormycosis. Appropriate treatments of CAM include strict glycemic control, extensive surgical debridement, and antifungal therapy with amphotericin B formulations.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Diabetic Ketoacidosis / Coinfection / COVID-19 / Mucormycosis Type of study: Experimental Studies / Observational study Topics: Long Covid Limits: Humans Country/Region as subject: Asia Language: English Journal: J Microbiol Immunol Infect Journal subject: Allergy and Immunology / Microbiology Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Diabetic Ketoacidosis / Coinfection / COVID-19 / Mucormycosis Type of study: Experimental Studies / Observational study Topics: Long Covid Limits: Humans Country/Region as subject: Asia Language: English Journal: J Microbiol Immunol Infect Journal subject: Allergy and Immunology / Microbiology Year: 2022 Document Type: Article